DNA damage: placing BRCA1 in the proper context.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current Biology

• Publication date

  2012-09-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cub.2012.07.046PMID 23017997PMCID PMC3827951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.

  2012cited by this paper
• BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

  2011cited by this paper
• BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity

  2011cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia.

  2008cited by this paper
• E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks

  2008cited by this paper
• Topoisomerase I inhibitors: camptothecins and beyond

  2006cited by this paper
• Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.

  2006cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation.

  2004cited by this paper
• BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting

  2003cited by this paper
• The BRCT Domain Is a Phospho-Protein Binding Domain

  2003cited by this paper
• Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex

  2003cited by this paper
• Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.

  2001cited by this paper

• Chaperoning HMGA 2 Protein Protects Stalled Replication Forks in Stem and Cancer Cells

  2019cites this paper
• The Role of Genetic Polymorphisms as Related to One-Carbon Metabolism, Vitamin B6, and Gene–Nutrient Interactions in Maintaining Genomic Stability and Cell Viability in Chinese Breast Cancer Patients

  2016cites this paper
• Mutations and Drugs Portal (MDP): A Database Linking Drug Response Data and Genomic Information

  2016cites this paper
• The Lys63-deubiquitylating Enzyme BRCC36 Limits DNA Break Processing and Repair*

  2016cites this paper
• Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells.

  2014cites this paper
• Distinct functional roles for the two SLX4 ubiquitin-binding UBZ domains mutated in Fanconi anemia

  2014cites this paper
• RNA-binding proteins in Mendelian disease.

  2013cites this paper
• Vitamin B12 and Methionine Deficiencies Induce Genome Damage Measured Using the Cytokinesis-Block Micronucleus Cytome Assay in Human B Lymphoblastoid Cell Lines

  2013cites this paper